NAGE
Niagen Bioscience, Inc.
$3.37
-0.08 (-2.32%)
At close · Jul 8
Market Cap
$277.96M
Shares
79,644,327
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$129.42M
+29.9%
FY2025
Net Income
$17.38M
+103.3%
FY2025
Gross Margin
64.28%
+2.4pp
FY2025
Operating Margin
12.58%
+4.8pp
FY2025
Diluted EPS
$0.20
+81.8%
FY2025
Operating Cash Flow
$13.5M
+11.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $130.42M | $129.42M | $99.6M | $83.57M | $72.05M | $67.45M | $59.26M | $46.29M | $31.56M | $21.2M | — | — | — | — | — | — | — | |
| $834K | — | — | $661K | $3000 | -$55K | — | — | — | — | — | — | — | — | — | — | — | |
| $46.58M | $46.23M | $38.01M | $32.79M | $29.25M | $25.96M | $23.98M | $20.52M | $15.5M | $10.72M | $11.27M | $10.35M | $9.99M | $7.03M | $9.34M | $5.64M | $4.62M | |
| $83.83M | $83.19M | $61.59M | $50.78M | $42.8M | $41.49M | $35.27M | $25.77M | $16.06M | $10.48M | $10.39M | $7.53M | $5.33M | $3.13M | $2.28M | $2.47M | $2.94M | |
| — | 64.28% | 61.84% | 60.76% | 59.4% | 61.51% | 59.53% | 55.67% | 50.88% | 49.42% | — | — | — | — | — | — | — | |
| $6.55M | $6.33M | $6.02M | $4.96M | $4.83M | $3.83M | $3.42M | $4.42M | $5.48M | $4.01M | $2.52M | $891.6K | $513.67K | $134.04K | $142K | $96.79K | — | |
| $37.06M | $35.51M | $29.47M | $26.44M | $28.31M | $28.35M | $20.95M | $18.22M | $16.54M | $4.46M | $1.56M | $1.51M | $2.14M | $2.36M | $5.52M | $2.54M | $1.09M | |
| $29.12M | $27.06M | $18.38M | $24.98M | $28.29M | $36.38M | $30.77M | $34.31M | $27.14M | $17.64M | $9.21M | $7.2M | $7.86M | $4.98M | $8.39M | $7.8M | $3.88M | |
| — | $173K | $151K | $158K | $186K | $225K | $243K | $246K | $235K | $206K | $87.83K | $45.01K | $35.59K | $23.53K | $15.93K | $70.25K | $73.64K | |
| — | — | — | — | — | — | — | — | $607K | $510K | $332K | $286K | $223K | $246K | — | — | — | |
| $70.75M | $66.91M | $53.86M | $56.38M | $61.43M | $68.56M | $55.13M | $57.07M | $49.23M | $26.85M | $13.3M | $9.6M | $10.56M | $7.52M | $13.91M | $10.34M | $4.96M | |
| $13.08M | $16.28M | $7.73M | -$5.6M | -$18.63M | -$27.07M | -$19.85M | -$31.3M | -$33.17M | -$16.38M | -$2.91M | -$2.07M | -$5.23M | -$4.39M | -$11.64M | -$7.86M | -$2.02M | |
| — | 12.58% | 7.76% | -6.7% | -25.85% | -40.14% | -33.5% | -67.62% | -105.12% | -77.25% | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | -$32.57M | -$15.87M | -$2.57M | -$1.78M | -$5.01M | -$4.14M | — | — | — | |
| $32K | — | — | — | — | $55K | $71K | $847K | $79K | $153K | $333.29K | $566.92K | $158.85K | $34.33K | $29.01K | -$32.14K | $36.07K | |
| — | $2.13M | $1.13M | — | — | — | — | — | — | — | $2247 | $3325 | $2013 | $1251 | $3014 | $1397 | $1545 | |
| -$78K | — | — | — | — | — | -$71K | -$847K | -$144K | -$153K | -$646.39K | -$566.92K | -$156.84K | -$33.08K | -$25.99K | -$30.75K | -$34.52K | |
| $19.7M | $18.19M | $8.86M | -$4.94M | — | — | — | — | — | -$16.53M | -$3.55M | -$2.63M | -$5.39M | -$4.42M | — | — | — | |
| $1.06M | $810K | $305K | $0 | — | — | — | — | — | $0 | $0 | -$4527 | $0 | — | — | — | — | |
| $18.64M | $17.38M | $8.55M | -$4.94M | -$16.54M | -$27.13M | -$19.93M | -$32.15M | -$33.32M | -$11.38M | -$2.93M | -$2.77M | -$5.39M | -$4.42M | -$11.66M | -$7.89M | -$2.05M | |
| — | 13.43% | 8.58% | -5.91% | -22.96% | -40.22% | -33.62% | -69.45% | -105.57% | -53.67% | — | — | — | — | — | — | — | |
| USD/shares | — | $0.22 | $0.11 | -$0.07 | -$0.24 | -$0.40 | -$0.33 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | $0.20 | $0.11 | -$0.07 | -$0.24 | -$0.40 | -$0.33 | — | — | — | — | — | — | — | — | -$0.12 | -$0.04 |
| shares | — | 79.18M | 75.93M | 74.99M | 69.73M | 67.19M | 61.07M | 57.06M | 55.01K | 44.6K | 37.29M | 35.88M | 35.49M | 99.99M | 90.27M | 68.31M | — |
| shares | — | 85.44M | 78.13M | 74.99M | 69.73M | 67.19M | 61.07M | 57.06M | 55.01K | 44.6K | 37.29M | 35.88M | 35.49M | 100.59M | 95.99M | 75.98M | 48.25M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2025: $663.2K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
16.62×
Biotechnology median 7.68×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Consumer Products Segment | $97,672,000 | $76,772,000 | $69,528,000 | $60,110,000 | $56,705,000 | $47,090,000 | $36,075,000 |
| Ingredients Segment | $28,675,000 | $19,814,000 | $11,137,000 | $8,736,000 | $7,407,000 | $9,198,000 | $6,196,000 |
| Analytical Reference Standards and Services Segment | $3,076,000 | $3,011,000 | $2,905,000 | $3,204,000 | $3,337,000 | $2,969,000 | $4,020,000 |
| Pharmaceuticals Segment | $0 | $0 | — | — | — | — | — |
| Other Segment | — | — | — | — | — | $0 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Consumer Products Segment | $28,426,000 | $17,177,000 | $14,486,000 | $6,509,000 | $5,593,000 | $6,254,000 | $483,000 |
| Ingredients Segment | $16,748,000 | $10,898,000 | $5,420,000 | $3,608,000 | $3,723,000 | $5,121,000 | $2,250,000 |
| Analytical Reference Standards and Services Segment | $396,000 | -$215,000 | -$522,000 | -$459,000 | -$10,000 | -$464,000 | $400,000 |
| Pharmaceuticals Segment | -$2,234,000 | -$1,759,000 | — | — | — | — | — |
| Other Segment | — | — | — | — | — | -$30,448,000 | -$34,433,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Consumer Products Segment | 29.1% | 22.4% | 20.8% | 10.8% | 9.9% | 13.3% | 1.3% |
| Ingredients Segment | 58.4% | 55% | 48.7% | 41.3% | 50.3% | 55.7% | 36.3% |
| Analytical Reference Standards and Services Segment | 12.9% | -7.1% | -18% | -14.3% | -0.3% | -15.6% | 10% |